ArticleThe Journal of clinical investigation2022

Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models.

Haohai Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.